Physician profile
David Moore
NPI 1942479530
$774.07
in general payments reported to CMS, 2019-2025
18 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $210 · 2021: $39.60 · 2022: $17.68 · 2024: $31.93 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $152.13 | 2019-2024 | Repatha, Krystexxa |
| Insulet Corporation | $123.07 | 2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.85 | 2019-2020 | |
| Pfizer INC. | $57.26 | 2019-2020 | |
| Exact Sciences Corporation | $49.05 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Vital Connect, INC | $44.58 | 2025 | Vitalpatch Rtm |
| Cvrx, INC. | $43.92 | 2025 | Barostim Neo System |
| Abbvie INC. | $36.18 | 2021-2022 | |
| Lilly USA, LLC | $31.62 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.17 | 2019-2020 | |
| Novo Nordisk INC | $29.67 | 2020-2025 | Wegovy |
| Astellas Pharma US INC | $21.10 | 2021 | |
| Abbott Laboratories | $19.38 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.63 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.54 | 2025 | Lifevest |
| Avanir Pharmaceuticals, INC. | $15.37 | 2020 | |
| Allergan, INC. | $13.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.